# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# HEALTH TECHNOLOGY APPRAISAL PROGRAMME

## Equality impact assessment – Guidance development

## MTA Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

## Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

A consultee noted that young drug abusers, recent immigrants and asylum seeker children should be considered in this appraisal to avoid any equality issues. The appraisal did not exclude any specific groups according to socioeconomic factors or behaviour.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No potential equality issues were raised.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No potential equality issues were identified by the Committee.

# 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other

Technology appraisals: Guidance development Equality impact assessment for the multiple technology appraisal of peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people Issue date: November 2013 groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

N/A. The summary table indicates potential issues raised at scoping.

### Approved by Associate Director (name): Elisabeth George

Date: 18/07/13

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No recommendations have changed following consultation.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

N/A. The summary table indicates potential issues raised at scoping.

### Approved by Centre or Programme Director (name): Elisabeth George

### Date: 03 10 2013

Technology appraisals: Guidance development Equality impact assessment for the multiple technology appraisal of peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people Issue date: November 2013